372 related articles for article (PubMed ID: 20634777)
21. Dose of intravitreal bevacizumab (Avastin) used as preoperative adjunct therapy for proliferative diabetic retinopathy.
Hattori T; Shimada H; Nakashizuka H; Mizutani Y; Mori R; Yuzawa M
Retina; 2010 May; 30(5):761-4. PubMed ID: 20453802
[TBL] [Abstract][Full Text] [Related]
22. Role of combined cataract surgery and intravitreal bevacizumab injection in preventing progression of diabetic retinopathy: prospective randomized study.
Cheema RA; Al-Mubarak MM; Amin YM; Cheema MA
J Cataract Refract Surg; 2009 Jan; 35(1):18-25. PubMed ID: 19101420
[TBL] [Abstract][Full Text] [Related]
23. Intravitreal injection of bevacizumab and triamcinolone acetonide at the end of vitrectomy for diabetic vitreous hemorrhage: a comparative study.
Park DH; Shin JP; Kim SY
Graefes Arch Clin Exp Ophthalmol; 2010 May; 248(5):641-50. PubMed ID: 20012643
[TBL] [Abstract][Full Text] [Related]
24. Can an intraoperative bevacizumab injection prevent recurrent postvitrectomy diabetic vitreous hemorrhage?
Romano MR; Gibran SK; Marticorena J; Wong D; Heimann H
Eur J Ophthalmol; 2009; 19(4):618-21. PubMed ID: 19551678
[TBL] [Abstract][Full Text] [Related]
25. Bevacizumab pretreatment in vitrectomy with silicone oil for severe diabetic retinopathy.
Yeh PT; Yang CM; Lin YC; Chen MS; Yang CH
Retina; 2009 Jun; 29(6):768-74. PubMed ID: 19516117
[TBL] [Abstract][Full Text] [Related]
26. Bevacizumab (Avastin) as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy: a prospective case series.
Abdelhakim MA; Macky TA; Mansour KA; Mortada HA
Ophthalmic Res; 2011; 45(1):23-30. PubMed ID: 20714187
[TBL] [Abstract][Full Text] [Related]
27. Intravitreal bevacizumab and panretinal photocoagulation for proliferative diabetic retinopathy associated with vitreous hemorrhage.
Huang YH; Yeh PT; Chen MS; Yang CH; Yang CM
Retina; 2009 Sep; 29(8):1134-40. PubMed ID: 19672218
[TBL] [Abstract][Full Text] [Related]
28. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
[TBL] [Abstract][Full Text] [Related]
29. Intravitreal triamcinolone acetonide injection at the end of vitrectomy for diabetic vitreous hemorrhage: a randomized, clinical trial.
Faghihi H; Taheri A; Farahvash MS; Esfahani MR; Rajabi MT
Retina; 2008 Oct; 28(9):1241-6. PubMed ID: 18626423
[TBL] [Abstract][Full Text] [Related]
30. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A
Retina; 2006; 26(9):999-1005. PubMed ID: 17151486
[TBL] [Abstract][Full Text] [Related]
31. Early vitreous hemorrhage after vitrectomy with preoperative intravitreal bevacizumab for proliferative diabetic retinopathy.
Sato T; Morita S; Bando H; Sato S; Ikeda T; Emi K
Middle East Afr J Ophthalmol; 2013; 20(1):51-5. PubMed ID: 23580852
[TBL] [Abstract][Full Text] [Related]
32. Influence of preoperative intravitreal bevacizumab on visual function in eyes with proliferative diabetic retinopathy.
Ushida H; Kachi S; Asami T; Ishikawa K; Kondo M; Terasaki H
Ophthalmic Res; 2013; 49(1):30-6. PubMed ID: 23038607
[TBL] [Abstract][Full Text] [Related]
33. Visual outcomes and incidence of recurrent vitreous hemorrhage after vitrectomy in diabetic eyes pretreated with bevacizumab (avastin).
Lo WR; Kim SJ; Aaberg TM; Bergstrom C; Srivastava SK; Yan J; Martin DF; Hubbard GB
Retina; 2009; 29(7):926-31. PubMed ID: 19584650
[TBL] [Abstract][Full Text] [Related]
34. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy.
Arevalo JF; Maia M; Flynn HW; Saravia M; Avery RL; Wu L; Eid Farah M; Pieramici DJ; Berrocal MH; Sanchez JG
Br J Ophthalmol; 2008 Feb; 92(2):213-6. PubMed ID: 17965108
[TBL] [Abstract][Full Text] [Related]
35. Vitreous and plasma concentrations of apelin and vascular endothelial growth factor after intravitreal bevacizumab in eyes with proliferative diabetic retinopathy.
Qian J; Lu Q; Tao Y; Jiang YR
Retina; 2011 Jan; 31(1):161-8. PubMed ID: 20890241
[TBL] [Abstract][Full Text] [Related]
36. Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema.
Soheilian M; Ramezani A; Bijanzadeh B; Yaseri M; Ahmadieh H; Dehghan MH; Azarmina M; Moradian S; Tabatabaei H; Peyman GA
Retina; 2007; 27(9):1187-95. PubMed ID: 18046223
[TBL] [Abstract][Full Text] [Related]
37. Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy.
di Lauro R; De Ruggiero P; di Lauro R; di Lauro MT; Romano MR
Graefes Arch Clin Exp Ophthalmol; 2010 Jun; 248(6):785-91. PubMed ID: 20135139
[TBL] [Abstract][Full Text] [Related]
38. Role of residual vitreous cortex removal in prevention of postoperative vitreous hemorrhage in diabetic vitrectomy.
Cheema RA; Mushtaq J; Cheema MA
Int Ophthalmol; 2010 Apr; 30(2):137-42. PubMed ID: 19169862
[TBL] [Abstract][Full Text] [Related]
39. Intravitreal bevacizumab (Avastin) prevention of panretinal photocoagulation-induced complications in patients with severe proliferative diabetic retinopathy.
Mason JO; Yunker JJ; Vail R; McGwin G
Retina; 2008 Oct; 28(9):1319-24. PubMed ID: 18667958
[TBL] [Abstract][Full Text] [Related]
40. Histology of fibrovascular membranes of proliferative diabetic retinopathy after intravitreal injection of bevacizumab.
Kubota T; Morita H; Tou N; Nitta N; Tawara A; Satoh H; Shimajiri S
Retina; 2010 Mar; 30(3):468-72. PubMed ID: 19952991
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
